STAB1 and myelodysplastic syndrome: In conclusion, ex vivo bexmarilimab single-agent does not have a cytotoxic effect on AML/MDS blast cells but MHC II expression in antigen-presenting cells is increased upon bexmarilimab treatment, especially in samples with low HLA-DR and high CLEVER-1 expression.